Chemical formula: C₆H₁₀N₂O₂ Molecular mass: 142.156 g/mol
Piracetam’s mode of action in cortical myoclonus is as yet unknown. Piracetam exerts its haemorrheological effects on the platelets, red blood cells, and vessel walls by increasing erythrocyte deformability and by decreasing platelet aggregation, erythrocyte adhesion to vessel walls and capillary vasospasm.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N06BX03 | Piracetam | N Nervous system → N06 Psychoanaleptics → N06B Psychostimulants, agents used for ADHD and nootropics → N06BX Other psychostimulants and nootropics |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| NOOTROPIL Film-coated tablet / Oral solution / Solution for injection | Υπουργείο Υγείας (CY) | MPI, EU: SmPC |
Piracetam is an active ingredient of these brands:
Austria (AT)Ecuador (EC)Estonia (EE)Finland (FI)France (FR)Germany (DE)Japan (JP)Malta (MT)Mexico (MX)
Netherlands (NL)Singapore (SG)South Africa (ZA)Spain (ES)
Tunisia (TN)Turkey (TR)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
